For patients with solid tumors, the following criteria apply: a. Hemoglobin ? 9.0 g/dl, b. Absolute lymphocyte count ? 1.0 x 10^9/L, c. Absolute neutrophil count ? 1.5 x 10^9/L, d. Platelets ? 100.0 x 10^9/L
Serum hemoglobin ? 9 g/dL; absolute neutrophil count ? 1.5 x 109/L; platelets ? 100 x 109/L.
Hematology Hemoglobin ? 9 g/dL (SI Units: 90 g/L) Platelet count < 75000/mm3 Absolute neutrophil count (ANC) < 1500/mm3
Has adequate bone marrow function, defined as: Platelet count >= 100 x 109/L Hemoglobin >= 9.0 g/dL Absolute neutrophil count >= 1.5 x 109/L.
At least one cytopenia (ANC < 1800/µL or platelet count < 100,000/µL or hemoglobin [Hgb] < 10 g/dL)
Bone marrow reserve consistent with: absolute neutrophil count ? 1.5 x 109/L, platelet count ? 100 x 109/L, and hemoglobin ? 9 g/dL (without transfusion) within 1 week preceding the administration of the study drugs;
Platelet count ? 100 × 109/L, hemoglobin ? 9.0 g/dL and absolute neutrophil count (ANC) ? 2.0 × 109 /L.
Platelet count ? 100,000, hemoglobin ? 9 g/dL
Platelet count > 100000 /mm3, hemoglobin (Hb) > 8 g/dL, absolute neutrophil count (ANC) 1500/mm3; the patient cannot be transfused in order to meet study entry criteria
Adequate hematologic function as indicated by i. Absolute neutrophil counts (ANC) ? 1,500/mm3 ii. Hemoglobin (Hgb) ? 8.0 g/dL iii. Platelet count ? 100,000/mm3
Hemoglobin ?4.0 g/dL. Absolute neutrophil count ?1.0 x 109/L and platelet count ?75 x 109/L
have adequate hematologic function, defined as having a hemoglobin ?8g/dL, an absolute neutrophil count (ANC) ?1.0 × 109/L, and platelet count ?75.0 x 109/L;
Hematologic: ANC 1.5 x 109/L, Hgb ? 9.0 g/dL and platelet count 100 x 109/L (platelet count > 75 x 109/L if documented evidence of bone marrow involvement).
Bone marrow reserve consistent with absolute neutrophil count (ANC) >= 1500 per micro liter (/mcL); platelet count >= 100,000/mcL; hemoglobin A1c (HbA1c) less than (<) 6.5 percent (%).
Absolute neutrophil count (ANC) ?1.0 x 109/l, hemoglobin ?8 g/dl, platelet count ? 100 x 10^9/l, prothrombin (INR) <1.5.
Subjects with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal disease (estimated glomerular filtration rate (eGFR) <30ml/min), hepatic (Alanine transaminase (ALT) 2.5 times upper limit of normal (>2.5xULN), bilirubin > 2x ULN), hematological (absolute neutrophil count (ANC) <1.0 x 109/L, platelet count <75x109/L or requires regular platelet transfusions to maintain a platelet count ? 75 x 109/L , hemoglobin <9g/dL), endocrine (glycated Haemoglobin (HbA1c)>7% or random glucose >200mg/dL), pulmonary (Forced Expiratory Volume in 1 second (FEV1) <70% of predicted value), cardiac (New York Heart Association (NYHA)) class III/IV, or neurological disease
Recovery from last induction course of chemotherapy (absolute neutrophil count [ANC] > 500 and platelet > 20,000)
No significant anemia (hemoglobin below 9.0 g/dL) or neutropenia (absolute neutrophil count [ANC] < 1000/mm^3)
Absolute neutrophil count (ANC) of < 1.5×109/L, or platelet count of < 100 ×109/L, or hemoglobin < 9g/dL;
Bone marrow impairment as evidenced by hemoglobin <10.0 g/dL, neutrophil count <1.0 × 109/L, platelets <100 × 109/L
Adequate bone marrow function as defined below: \r\n• Absolute neutrophil count ? 1.5x109 /L (1500 per mm3) \r\n• Platelets ? 100x109 /L (100,000 per mm3) \r\n• Hemoglobin > 9.0 g/dL
Peripheral blood (PB) showing at least two of the following criteria: Absolute neutrophil count (ANC) < 0.5 k/µL Platelet count < 30 k/µL Absolute reticulocyte count < 60,000/µL
Has hemoglobin ? 10 g/dL, ANC ? 1.5 × 109/L, and platelet count ? 100 × 109/L
Absolute neutrophil count < 1,500/?L, platelet count < 100,000/?L, or hemoglobin < 6.2 mmol/L (10 g/dL) at screening
Patients must have a platelet count > 100,000/µL, hemoglobin ? 10.0 gm/dL, white blood cell count (WBC) > 2,000/uL, absolute neutrophil count (ANC) ? 1.5 x 109/L, and a serum creatinine ? 1.5 mg/dL unless the measured creatinine clearance is > 40 mL/min/1.73 m2.
In patients < 18 years of age, moderately severe aplastic anemia is defined as having at least one of the following:\r\n* Platelet count < 40 x 10^9/L\r\n* Absolute neutrophil count (ANC) < 10 x 10^8/L\r\n* Hemoglobin (Hgb) < 9 g/dL
Laboratory test results within these ranges: Absolute neutrophil count ? 1.0 x 109/L, Platelet count ? 50 x 109/L, Serum creatinine ? 1.5 mg/dL, Total bilirubin ? 1.5 mg/dL, AST & ALT ? 2 x ULN
Absolute granulocyte count of ?1,000/?L, platelet count ?50,000/?L, and hemoglobin ?8.0 g/dL, with no transfusion within the preceding 7 days
Adequate organ function as defined by the following criteria: Absolute neutrophil count (ANC) ? 1500/?l, Platelets ? 140,000/?l,Hemoglobin ? 12.0 g/dl, Creatinine < 2.0 mg/dl
Bone Marrow Reserve: absolute neutrophil count ? 1.5 x 10^9/L; platelet count ? 100 x 10^9/L; hemoglobin ? 9.0 g/dL. Must not have required blood transfusion within 1 week of baseline blood count assessment.
Adequate hematologic function: Absolute neutrophil count (ANC) ? 1.0 109/L, platelet count ? 100.0 109/L and hemoglobin ? 8.0 g/dL (patients with bone marrow involvement will not be evaluable for hematologic DLT and can enroll with ANC ? 0.75 109/L, platelet count ? 50.0 109/L and hemoglobin ? 8.0 g/dL)
Absolute neutrophil count (ANC) ?1.0 x 109 /L, hemoglobin ?8 g/dL, and platelet count ? 75 x 109/L.
Adequate bone marrow function, for Portion A: absolute neutrophil count (ANC) ? 1.5 x 109/L, platelet count ?100 x 109/L, hemoglobin >9.0 g/dL. For Portion B: ANC ? 1.0 x 109/L, platelet count ? 75 x 109/L, and hemoglobin ? 8.0 g/dL. In both cases, patients must be transfusion independent at least 14 days prior to screening.
Inadequate bone marrow function per protocol-specified hemoglobin, platelet count, and absolute neutrophil count
Platelet count < 50 x10^9/L or absolute neutrophil count (ANC) < 1 x10^9/L at the Screening visit
Patient must have adequate bone marrow function as evidenced by absolute neutrophil count ?1.5 ×10^9/L; hemoglobin >9 g/dL (Patients are allowed to be transfused to this level); platelets ?75 × 10^9/L
Meets absolute neutrophil count, platelet count, hemoglobin, liver and kidney function laboratory values within 2 weeks prior to first dose of study drug.
Subject has absolute neutrophil count < 1500/?L, platelet count < 100000/?L or hemoglobin < 10 g/dL (6.2 mmol/L).
Blood counts at screening: haemoglobin ? 9.0 g/dl,absolute neutrophil count ? 1500/µl, platelet count ? 100,000/µl.
Absolute neutrophil count < 1000/?L, platelet count < 100,000/?L, or hemoglobin < 10 g/dL (6.2 mmol/L) at screening;
Hematological: Absolute neutrophil count ?1x10^9/L; Platelet count ?75x10^9/L;Hemoglobin ?8g/dL
Adequate bone marrow function as assessed by absolute neutrophil count (ANC) ? 1500/mm3; hemoglobin ? 9.0 g/dL, and platelet count ? 100,000/mm3.
Bone marrow reserve: Absolute neutrophil count (ANC) ? 1.5 x 109/L. Platelets ? 100 x 109/L. Hemoglobin ? 9 g/dL.
Hematological function: hemoglobin >9 g/dL; lymphocyte count >0.50 x 109/L; neutrophil count >1.5 x 109/L; platelet count >100 x 109/L
Patients with severe hematopoietic insufficiency, as defined by an absolute neutrophil count of less than 500/MuL, unless disease-related, and/or a platelet count of less than 30,000/MuL at time of screening for this protocol
There is no specific platelet and absolute neutrophil count that will exclude patients from this study given the natural history of AML
Adequate hematology laboratory results (absolute neutrophil count ? 1.5 x 10^9/L, platelet count ? 75 x 10^9/L, hemoglobin ? 10.0 g/dL).
Has adequate bone marrow function defined as a hemoglobin > 9 g/dL, absolute neutrophil count (ANC) ?1.5 ×10?/L , and platelet count ?100,000/mm³. For subjects who received chemotherapy for melanoma just prior to screening for the study subject needs to have a hemoglobin > 9 g/dL, absolute neutrophil count (ANC) >2 × 10?/L, and platelet count ?100,000/mm³.
Adequate hematologic, hepatic, and renal function (absolute neutrophil count ?1.5x 109/L, Hgb >10 g/dL, platelet count ?100 x 109/L, AST/ALT ?2.5x ULN, creatinine ?1.5x ULN).
Prior to day 1 of brentuximab vedotin, patients must again meet the following criteria:\r\n* Hemoglobin >= 8 g/dL\r\n* Absolute neutrophil count (ANC) >= 1,000 cells/mm^3\r\n* Platelet count >= 75,000/mm^3\r\n* Maximum Child-Pugh score of 5\r\n* Creatinine clearance > 50 mL/min via Cockcroft and Gault
Patients who have had count recovery (absolute neutrophil count [ANC] > 500,000/mm^3; non transfused platelet count over 30,000/mm^3) and are at least 30 days after induction and/or transplantation but no more than 120 days post transplant
Platelet count > 400 × 10^9/L and WBC count < 2.5 × 10^9/L or hemoglobin < 10 g/dL at any dose of hydroxyurea.
Adequate hematological function defined by white blood cell (WBC) count ?3 × 10^9/L; absolute neutrophil count (ANC) ?1.5 × 10^9/L; lymphocyte count ?0.5 × 10^9/L; platelet count ?100 × 10^9/L; and hemoglobin ?9 g/dL (may have been transfused).
Adequate hematological function, defined as WBC ?3 × 10^9/L; ANC ?1.5 × 10^9/L; lymphocyte count ?0.5 × 10^9/L; platelet count ?100 × 10^9/L; and hemoglobin ?9 g/dL (may have been transfused).
Bone Marrow Function: Patients must have adequate bone marrow function defined as a peripheral absolute neutrophil count ? 1000/µl, platelet count ? 100,000/µl (transfusion independent) and hemoglobin ? 8.0 gm/dL
No unexplained absolute eosinophil count > 1.5x10^9/L
Group 4: Patients who meet group 1 inclusion criteria but may have FVC or DLCO-adjusted less than 70% plus have had an adverse event on cyclophosphamide preventing its further use (specifically hemorrhagic cystitis, leukopenia with white blood cell [WBC]< 2000 or absolute neutrophil count [ANC] < 1000 or platelet count < 100,000)
Absolute neutrophil count < 1,500/?L, platelet count < 75,000/?L, or hemoglobin < 5.6 mmol/L (9 g/dL) at screening.
Subjects must have adequate bone marrow function as assessed by the following: hemoglobin >=9.0 g/dL or >=5.6 mmol/L, absolute neutrophil count (ANC) >=1.500/mm^3 or >=1.5 x 10^9/L (CTCAE Grade <=1), platelet count >= 100000/mm^3 or >=100 x 10^9/L
Hematologic function: Absolute neutrophil count (ANC) > 500/?L and platelet count > 25,000/?L without transfusion
Hematological: Absolute neutrophil count (ANC) ? 1.5 x 10^9/L, platelet ? 100 x 10^9/L, hemoglobin ? 9 g/dL
12. Adequate bone marrow function (hemoglobin ? 9.0 g/dL; platelets ? 100 x 109/L; absolute neutrophil count [ANC] ? 1.5 x 109/L) without the use of hematopoietic growth factors.
The following laboratory parameters must be within the ranges specified: Hemoglobin ? 10 g/dL, Neutrophil count ? 1.5 x 109/L, Lymphocyte count ? LLN Platelet count ? 80 x 109/L, Serum creatinine ? 2 mg/dL, Serum bilirubin ? 2 x ULN, AST/ALT ? 2 x ULN.
Platelet count ? 100 x 109/L, absolute neutrophil count (ANC) ? 1.5 x 109/L, Hemoglobin ? 9 g/dL.
Hemoglobin ? 7.5 g/dL, - Absolute neutrophil count ? 1.0 x 109/L (1000/mm3), - Platelets ? 50,000/?L
Subject has absolute neutrophil count < 1000/?L, platelet count < 75,000/?L, and hemoglobin < 8 g/dL (< 5 mmol/L) at Screening
Adequate bone marrow function (subjects other than those with AITL) as evidenced by: absolute neutrophil count ?1.0 ×109/L;hemoglobin >9 g/dL (Subjects may be transfused red blood cells to this level.); platelets ?50 × 109/L
Has adequate bone marrow function, defined as: Platelet count >= 100 X 10*9/L Hemoglobin level >= 9.0 g/dL Absolute neutrophil count >= 1.5 x 10*9/L
Adequate baseline hematological parameters as defined by white blood cell count (WBC) ? 3.5 x 103/µL, lymphocyte count ? 1.0 x 103/µL, platelet count ? 100 x 103/µL, and hemoglobin ? 9 g/dL
Platelet count ? 100,000/cubic millimeters (mm3), hemoglobin (Hb) ? 8.5 g/dl, leukocyte count > 3,000/mm3, absolute neutrophil count (ANC) ? 1,000/mm3
Patients must have adequate bone marrow function, defined as an absolute neutrophil count >= 1.5 x 10^9/L and a platelet count >= 100 x 10^9/L.
Whole Blood Cells (WBC) ?3.0 x 10?/L, Absolute neutrophil count (ANC) ?1.5 x 10?/L and platelet count ?100 x 10?/L
Hemoglobin ? 8.5 mg/dl 14. Absolute neutrophil count ? 1.5 x 10^9/L 15. Platelets ? 75 x 10^9/L 16. Life expectancy ? 3 months
Bone marrow: Absolute Neutrophil Count (ANC) ? 1.5 x 109/L, Hemoglobin (Hgb) ? 9 g/dL, Platelets ? 100 x 109/L
The participant has adequate hematologic function as defined by absolute neutrophil count ? 1500/microliters (?L), hemoglobin ? 9 gram/deciliter (g/dL), and platelet count ?100,000/?L
Bone marrow function: neutrophil count >/=1,000/mm3, platelet count >/= 75,000/mm3 and hemoglobin concentration >/= 8.0 g/dL.
Acceptable laboratory results during screening and prior to first study drug administration of the following parameters: absolute neutrophil count (ANC), platelet count, hemoglobin, total bilirubin, aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT), renal function based on estimated creatinine clearance
Adequate bone marrow function, defined as an absolute neutrophil count (ANC) of greater than or equal to (>=) 1.5*109 per liter (/L), platelet count >=100*109/L, and hemoglobin >=9 gram per deciliter (g/dL). Receiving transfusions or hematopoietic growth factors to meet enrollment criteria is not allowed within 14 days preceding the first dose of study drug.
Platelet count ? 100 x 109/l, hemoglobin ? 9.0 g/dl and ANC ? 1.0 x 109/l.
Hemoglobin must be >=8 gram per deciliter (g/dL), absolute neutrophil count (ANC) must be >=1500 per microliter (/mcL), and platelet count must be >=75,000/mcL.
Bone marrow reserve consistent with absolute neutrophil count (ANC) ?1.5*10^9/L; platelet count ?100*10^9/L; hemoglobin (Hgb) ?9 g/dL.